TMCnet News
Hepatitis B Virus (HBV) Therapeutics Report 2016 - 5EU Drug Forecast and Market Analysis to 2024 - Research and MarketsResearch and Markets has announced the addition of the "Hepatitis B Virus (HBV) Therapeutics - 5EU Drug Forecast and Market Analysis to 2024" report to their offering. The chronic hepatitis B therapeutics market in the 5EU was valued at $532.1m in 2014. The anticipated arrival of novel branded therapies will be the strongest market driver in the 5EU during the forecast period. These therapies include Gilead's TAF, a novel NA, along with three adjunct therapies, Arrowhead's ARC-520, Gilead's GS-9620, and Gilead's GS-4774. GlobalData projects these four products will receive licensure in the 5EU in 2017, 2021, 2021, and 2023, respectively. Scope - Overview of HBV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in 5EU, including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for thetop drugs in 5EU from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting the 5EU HBV market. Key Topics Covered: 1. Tables & Figures 2 Introduction 2.1 Catalyst 2.2 Related Reports 2.3 Upcoming Related Reports 3 Disease Overview 3.1 Overview 3.2 Etiology and Pathophysiology 3.3 Symptoms 3.5 Quality of Life 4 Disease Management 4.1 Diagnosis and Treatment Overview 4.2 5EU 5 Competitive Assessment 5.1 Overview 5.2 Product Profiles - Major Brands 5.3 Other Therapeutics 6 Unmet Need and Opportunity 6.1 Overview 6.2 Improvements in Long-Term Clinical Outcomes 6.3 Enhanced Public Awareness and Screening Initiatives to Boost Diagnosis Rates 6.4 Increased Access to Treatment 6.5 Drugs That Effectively Target (News - Alert) and Suppress HBV cccDNA 6.6 Safe and Efficacious Therapies for Difficult-to-Treat Patients 6.7 Overcome Unique Barriers Posed by China's Healthcare System 7 Pipeline Assessment 7.1 Overview 7.2 Clinical Trial Mapping 7.3 Promising Drugs in Clinical Development 7.4 Other Drugs in Development 8 Market Outlook 8.1 5EU 9 Appendix For more information visit http://www.researchandmarkets.com/research/h8gk3x/hepatitis_b_virus.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160622006283/en/ |